Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment Selection
Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.
Steps Nurses Can Take to Improve Health Equity in Cancer Clinical Trials
A key component of health equity includes ensuring that clinical trials reflect subgroups of patients who are more reflective of real-world populations.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung Cancer
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.
Distress in Advanced Cancer May Be Alleviated With Psychedelic-Assisted Psychotherapy
Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.
Evolving Immunotherapy Data Shed Light on Best Practices in Metastatic Melanoma
During the 40th Annual Chemotherapy Foundation Symposium, Jeffrey S. Weber, MD, PhD, discussesed best sequencing practices in metastatic melanoma.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian Cancer
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Manmeet Ahulwalia, MD, MBA, underscores how novel treatment approaches in oncology are proving effective in managing brain metastases.
Health Literacy in Cancer Care Begins with the Nursing Staff
During the 40th Annual Chemotherapy Foundation Symposium, Sandra Kurtin, PhD, ANP-BC, FAPO, discussed improving health literacy in oncology care.
Significant Gaps Still Remain in The Treatment of Breast Cancer
During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Daniel J. Verina, DNP, RN, MSN, ACNP-BC, underscores how nurses can assess neurological toxicities in both the inpatient and outpatient setting.
Maximizing Potential of Immunotherapy Requires Appropriate irAE Management
Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.
Inclusivity Must Be Made A Priority in Clinical Trials and Cancer Care
Narjust Florez, MD, emphasizes why oncology health care professionals should bring a sense of urgency to ensuring that clinical trials represent all patient populations.
How To Choose Immunotherapy or BRAF-Targeted Treatment for Adjuvant Melanoma
There is still a great deal to learn about the optimal use of BRAF-targeted therapy, as well as immunotherapy, in the adjuvant setting for patients with melanoma.
Orca-T Provides Post-HCT Survival Benefits vs PTCy in Blood Cancers
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
2 Commerce Drive Cranbury, NJ 08512